Neeltje Steeghs
Neeltje Steeghs
Geverifieerd e-mailadres voor
Geciteerd door
Geciteerd door
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
Pan-cancer whole-genome analyses of metastatic solid tumours
P Priestley, J Baber, MP Lolkema, N Steeghs, E de Bruijn, C Shale, ...
Nature 575 (7781), 210-216, 2019
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
N Steeghs, H Gelderblom, J Op't Roodt, O Christensen, P Rajagopalan, ...
Clinical Cancer Research 14 (11), 3470-3476, 2008
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets
H Yu, N Steeghs, CM Nijenhuis, JHM Schellens, JH Beijnen, ...
Clinical pharmacokinetics 53 (4), 305-325, 2014
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments
N Steeghs, JWR Nortier, H Gelderblom
Annals of surgical oncology 14 (2), 942-953, 2007
Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology
RB Verheijen, H Yu, JHM Schellens, JH Beijnen, N Steeghs, ...
Clinical Pharmacology & Therapeutics 102 (5), 765-776, 2017
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
KM Heinhuis, W Ros, M Kok, N Steeghs, JH Beijnen, JHM Schellens
Annals of Oncology 30 (2), 219-235, 2019
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors
N Steeghs, FALM Eskens, H Gelderblom, J Verweij, JWR Nortier, ...
Journal of Clinical Oncology 27 (30), 5094-5101, 2009
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
L Angus, M Smid, SM Wilting, J van Riet, A Van Hoeck, L Nguyen, ...
Nature genetics 51 (10), 1450-1458, 2019
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
A Kollár, RL Jones, S Stacchiotti, H Gelderblom, M Guida, G Grignani, ...
Acta oncologica 56 (1), 88-92, 2017
The mutational footprints of cancer therapies
O Pich, F Muiños, MP Lolkema, N Steeghs, A Gonzalez-Perez, ...
Nature genetics 51 (12), 1732-1740, 2019
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care
NAG Lankheet, LM Knapen, JHM Schellens, JH Beijnen, N Steeghs, ...
Therapeutic drug monitoring 36 (3), 326-334, 2014
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
NAG Lankheet, JSL Kloth, CGM Gadellaa-van Hooijdonk, GA Cirkel, ...
British journal of cancer 110 (10), 2441-2449, 2014
Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin …
WWJ de Leng, CG Gadellaa-van Hooijdonk, FAS Barendregt-Smouter, ...
PloS one 11 (2), e0149405, 2016
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662
MHM Diekstra, HJ Klümpen, M Lolkema, H Yu, JSL Kloth, H Gelderblom, ...
Clinical Pharmacology & Therapeutics 96 (1), 81-89, 2014
Molecular tumor boards: current practice and future needs
DL Van der Velden, CML Van Herpen, HWM Van Laarhoven, EF Smit, ...
Annals of Oncology 28 (12), 3070-3075, 2017
Simple and safe exclusion of pulmonary embolism in outpatients using quantitative D-dimer and Wells’ simplified decision rule
RJ Goekoop, N Steeghs, RWLM Niessen, GJPM Jonkers, H Dik, A Castel, ...
Thrombosis and haemostasis 97 (01), 146-150, 2007
Cisplatin-induced encephalopathy and seizures
N Steeghs, FE De Jongh, PAES Smitt, MJ Van den Bent
Anti-cancer drugs 14 (6), 443-446, 2003
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
F Meric-Bernstam, SK Sandhu, O Hamid, A Spreafico, S Kasper, ...
Journal of Clinical Oncology 37 (15_suppl), 2507-2507, 2019
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
JSL Kloth, A Pagani, MC Verboom, A Malovini, C Napolitano, WHJ Kruit, ...
British journal of cancer 112 (6), 1011-1016, 2015
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20